< Back
EMWA Logo EMWA Logo
 

Tiziana von Bruchhausen

Company:
Boehringer Ingelheim
Qualification:
PhD
Leader background:
Tiziana specialises in pharmacovigilance writing and has gained over 10 years’ experience while working in various roles for mid-sized and large pharmaceutical companies. She is currently employed as a senior pharmacovigilance writer at Boehringer Ingelheim. Her tasks and responsibilities cover pre- and post-submission activities related to the global strategic planning and the preparation of pharmacovigilance documents with a focus on DSURs, RMPs, PSURs, and health authorities’ assessment reports. Tiziana actively promotes the professional role of medical writers in pharmacovigilance through workshops and lectures Europe-wide and has served as a session chair at international conferences. She is an active volunteer at the European Medical Writers Association (EMWA), where she has been chairing since 2017 the Pharmacovigilance Special Interest Group Committee. She was Vice President of EMWA in 2017-2018 and President in 2018-2019.
Workshops:
Risk Management Plans: Challenges and insights
    Level: Advanced Area: Drug Development
    Code: DDA20 Duration: 03:30:00
Writing Risk Management Plans
    Level: Foundation Area: Drug Development
    Code: DDF30 Duration: 03:30:00
Introduction to Pharmacovigilance Writing
    Level: Foundation Area: Drug Development
    Code: DDF32 Duration: 03:00:00
Post-submission Pharmacovigilance Writing: Interactions with Authorities and Impact on RMPs and PSURs
    Level: Advanced Area: Drug Development
    Code: DDA26 Duration: 03:30:00
Periodic Benefit-Risk Evaluation Reports
    Level: Advanced Area: Drug Development
    Code: DDA14b Duration: 03:30:00
Introduction to Pharmacovigilance Writing
    Level: Foundation Area: Drug Development
    Code: DDF32a Duration: 03:00:00
Writing Development Safety Update Reports
    Level: Advanced Area: Drug Development
    Code: DDA32a Duration: 03:30:00
Introduction to Pharmacovigilance Writing
    Level: Foundation Area: Drug Development
    Code: DDF32b Duration: 03:00:00
Periodic Benefit-Risk Evaluation Reports
    Level: Advanced Area: Drug Development
    Code: DDA14c Duration: 03:30:00